ALT – Altimmune Inc
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ALT
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=ALT
&conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]
Float Short %
30.63
Margin Of Safety %
Put/Call OI Ratio
0.19
EPS Next Q Diff
-0.05
EPS Last/This Y
0.21
EPS This/Next Y
-0.26
Price
3.63
Target Price
18.44
Analyst Recom
1.6
Performance Q
-49.09
Relative Volume
0.31
Beta
0.07
Ticker: ALT
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | ALT | 3.62 | 0.26 | 0.20 | 191991 |
| 2025-08-18 | ALT | 3.55 | 0.26 | 0.16 | 180668 |
| 2025-08-19 | ALT | 3.6 | 0.25 | 0.21 | 184384 |
| 2025-08-20 | ALT | 3.62 | 0.25 | 0.39 | 187920 |
| 2025-08-21 | ALT | 3.53 | 0.25 | 0.21 | 190162 |
| 2025-08-22 | ALT | 3.54 | 0.25 | 0.17 | 190912 |
| 2025-08-25 | ALT | 3.39 | 0.25 | 0.33 | 189184 |
| 2025-08-26 | ALT | 3.43 | 0.25 | 0.63 | 190869 |
| 2025-08-27 | ALT | 3.66 | 0.24 | 0.24 | 191819 |
| 2025-08-28 | ALT | 3.7 | 0.24 | 0.23 | 197158 |
| 2025-08-29 | ALT | 3.82 | 0.24 | 0.28 | 202336 |
| 2025-09-02 | ALT | 3.75 | 0.21 | 1.02 | 197976 |
| 2025-09-03 | ALT | 3.67 | 0.22 | 0.74 | 201724 |
| 2025-09-04 | ALT | 3.55 | 0.22 | 0.58 | 203018 |
| 2025-09-05 | ALT | 3.78 | 0.22 | 0.33 | 203544 |
| 2025-09-08 | ALT | 3.7 | 0.18 | 0.39 | 198096 |
| 2025-09-09 | ALT | 3.78 | 0.19 | 0.15 | 199497 |
| 2025-09-10 | ALT | 3.67 | 0.19 | 0.31 | 201371 |
| 2025-09-11 | ALT | 3.68 | 0.19 | 0.31 | 203752 |
| 2025-09-12 | ALT | 3.63 | 0.19 | 0.14 | 204919 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | ALT | 3.62 | 8.4 | -8.5 | -1.12 |
| 2025-08-18 | ALT | 3.56 | 16.2 | 9.0 | -1.12 |
| 2025-08-19 | ALT | 3.62 | 8.4 | -15.7 | -1.12 |
| 2025-08-20 | ALT | 3.62 | 8.4 | -12.2 | -1.12 |
| 2025-08-21 | ALT | 3.53 | 8.4 | -5.9 | -1.12 |
| 2025-08-22 | ALT | 3.53 | 16.2 | -12.2 | -1.12 |
| 2025-08-25 | ALT | 3.38 | 16.2 | -2.2 | -1.12 |
| 2025-08-26 | ALT | 3.44 | 16.2 | -15.5 | -1.12 |
| 2025-08-27 | ALT | 3.66 | 16.2 | -26.1 | -1.12 |
| 2025-08-28 | ALT | 3.71 | 16.2 | -14.3 | -1.12 |
| 2025-08-29 | ALT | 3.82 | 16.2 | -18.4 | -1.12 |
| 2025-09-02 | ALT | 3.75 | 16.2 | -8.1 | -1.13 |
| 2025-09-03 | ALT | 3.68 | 16.2 | -75.3 | -1.13 |
| 2025-09-04 | ALT | 3.55 | 16.2 | -69.5 | -1.13 |
| 2025-09-05 | ALT | 3.78 | 16.2 | -105.0 | -1.13 |
| 2025-09-08 | ALT | 3.71 | 16.2 | -75.7 | -1.13 |
| 2025-09-09 | ALT | 3.78 | 16.2 | -88.8 | -1.13 |
| 2025-09-10 | ALT | 3.67 | 16.2 | -72.1 | -1.13 |
| 2025-09-11 | ALT | 3.69 | 16.2 | -83.6 | -1.13 |
| 2025-09-12 | ALT | 3.63 | 16.2 | -76.0 | -1.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | ALT | 1.20 | -5.32 | 29.50 |
| 2025-08-18 | ALT | 1.20 | -1.14 | 29.50 |
| 2025-08-19 | ALT | 1.20 | -1.14 | 29.50 |
| 2025-08-20 | ALT | 1.20 | -1.14 | 29.50 |
| 2025-08-21 | ALT | 1.20 | -1.14 | 29.50 |
| 2025-08-22 | ALT | 1.20 | -1.14 | 29.50 |
| 2025-08-25 | ALT | 1.20 | -1.37 | 29.49 |
| 2025-08-26 | ALT | 1.21 | -1.37 | 29.49 |
| 2025-08-27 | ALT | 1.21 | -1.37 | 29.15 |
| 2025-08-28 | ALT | 1.21 | -1.37 | 29.15 |
| 2025-08-29 | ALT | 1.21 | -1.37 | 29.15 |
| 2025-09-02 | ALT | 1.21 | -1.36 | 29.15 |
| 2025-09-03 | ALT | 1.29 | -1.36 | 29.13 |
| 2025-09-04 | ALT | 1.29 | -1.36 | 29.13 |
| 2025-09-05 | ALT | 1.29 | -1.36 | 29.13 |
| 2025-09-08 | ALT | 1.29 | -1.38 | 29.13 |
| 2025-09-09 | ALT | 1.29 | -1.38 | 29.13 |
| 2025-09-10 | ALT | 1.29 | -1.38 | 29.13 |
| 2025-09-11 | ALT | 1.29 | -1.38 | 30.63 |
| 2025-09-12 | ALT | 1.29 | -1.38 | 30.63 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ALT
589 360 ]
Last Quarter Act. EPS
-0.27
Avg. EPS Est. Current Quarter
-0.27
Avg. EPS Est. Next Quarter
-0.32
Insider Transactions
1.29
Institutional Transactions
-1.38
Beta
0.07
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
23
Growth Score
22
Sentiment Score
30
Actual DrawDown %
85.3
Max Drawdown 5-Year %
-91.2
Target Price
18.44
P/E
Forward P/E
PEG
P/S
16062.86
P/B
1.92
P/Free Cash Flow
EPS
-1.18
Average EPS Est. Cur. Y
-1.13
EPS Next Y. (Est.)
-1.4
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-438730
Relative Volume
0.31
Return on Equity vs Sector %
-79.2
Return on Equity vs Industry %
-66.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.1
EBIT Estimation
-76
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ALT
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ALT
589 450 ]
Altimmune, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 59
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
stock quote shares ALT – Altimmune Inc Stock Price stock today
news today ALT – Altimmune Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALT – Altimmune Inc yahoo finance google finance
stock history ALT – Altimmune Inc invest stock market
stock prices ALT
premarket after hours
ticker ALT
fair value insiders trading